Pharmaceutical Firm “Darnitsa” has been the leader in the sale of medicinal products by volume since 1998. The strategic directions of the product portfolio development of the company are cardiology, neurology and pain problems. Each 7 pack of medicines in pharmacy shelves is manufactured by Darnitsa.
The company’s net income from sales in 2018 grew by 18.7%, to UAH 3.002 billion. Over the past 10 years, the company has invested more than 200 million euros into technical development. 10% of gross profit is invested annually in development, in particular R&D. The Company’s portfolio includes nearly 250 names of finished medicinal products. The products of “Pharmaceutical Firm “Darnitsa” PrJSC are exported to 16 countries.